Cryo-Cell International, Inc. (NYSEAMERICAN:CCEL) Short Interest Up 140.9% in March

Cryo-Cell International, Inc. (NYSEAMERICAN:CCEL) was the target of a significant increase in short interest in the month of March. As of March 15th, there was short interest totalling 26,500 shares, an increase of 140.9% from the February 29th total of 11,000 shares. Based on an average daily volume of 8,800 shares, the short-interest ratio is currently 3.0 days. Approximately 0.7% of the company’s shares are sold short.

Institutional Investors Weigh In On Cryo-Cell International

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Cerity Partners LLC purchased a new stake in shares of Cryo-Cell International in the fourth quarter worth about $83,000. Northern Trust Corp purchased a new position in Cryo-Cell International in the fourth quarter valued at about $151,000. Finally, Vanguard Group Inc. boosted its holdings in Cryo-Cell International by 13.7% in the third quarter. Vanguard Group Inc. now owns 83,883 shares of the company’s stock valued at $441,000 after purchasing an additional 10,095 shares during the last quarter. 10.44% of the stock is currently owned by institutional investors and hedge funds.

Cryo-Cell International Stock Performance

Shares of NYSEAMERICAN:CCEL traded down $0.54 during midday trading on Thursday, reaching $7.46. The company’s stock had a trading volume of 38,038 shares, compared to its average volume of 9,957. The firm has a market cap of $61.84 million, a price-to-earnings ratio of 17.48 and a beta of 0.41. Cryo-Cell International has a 1 year low of $2.95 and a 1 year high of $8.15. The company’s 50 day moving average is $5.69.

Cryo-Cell International (NYSEAMERICAN:CCEL) last announced its quarterly earnings results on Wednesday, February 28th. The company reported $0.26 EPS for the quarter. The company had revenue of $7.88 million during the quarter. Cryo-Cell International had a negative return on equity of 120.29% and a negative net margin of 30.38%.

Cryo-Cell International Company Profile

Cryo-Cell International, Inc engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, auto-immune diseases, multiple sclerosis, Alzheimer's disease, Parkinson's diseases.